Methylprednisolone hemisuccinate

Generic Name: Methylprednisolone hemisuccinate

Brand Names: Solu-medrol

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₄O_₈

CAS Number: 2921-57-5

Unique Ingredient Identifier: 5GMR90S4KN

Background: A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Associated Conditions: Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis

Associated Therapies: Palliative Treatment

Clinical Trials

Depomedrol for Genicular Nerve Block.

Not Applicable

Completed

Conditions: Postoperative Pain

Interventions: Drug: Bupivacaine Hcl 0.5% Inj_#2
Drug: Methylprednisolone Injection
Drug: normal saline

First Posted Date: 2023-06-08

Last Posted Date: 2023-11-29

Lead Sponsor: Menoufia University

Target Recruit Count: 48

Registration Number: NCT05893771

Locations: 🇪🇬
Menoufia University hospitals, Shibīn Al Kawm, Menoufia, Egypt

Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis

Phase 3

Recruiting

Conditions: Lupus Nephritis
Remission
Safety Issues

Interventions: Drug: Methylprednisolone Injectable Suspension
Drug: Belimumab Injection
Drug: Immunosuppressive Agents

First Posted Date: 2023-05-18

Last Posted Date: 2023-05-18

Lead Sponsor: Nanjing University School of Medicine

Target Recruit Count: 15

Registration Number: NCT05863936

Locations: 🇨🇳
Jiong Zhang, Nanjing, Jiangsu, China

Methylprednisolone Taper After Total Knee Replacement

Phase 4

Active, not recruiting

Conditions: Knee Arthritis

Interventions: Other: Standard of Care
Drug: Methylprednisolone

First Posted Date: 2023-05-15

Last Posted Date: 2025-04-17

Lead Sponsor: Emory University

Target Recruit Count: 101

Registration Number: NCT05859269

Locations: 🇺🇸
Emory Musculoskeletal Institute, Atlanta, Georgia, United States
🇺🇸
Emory University Orthopaedics & Spine Hospital, Tucker, Georgia, United States

Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Not Applicable

Active, not recruiting

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Methylprednisolone
Drug: Azithromycin

First Posted Date: 2023-05-06

Last Posted Date: 2025-05-14

Lead Sponsor: Assiut University

Target Recruit Count: 30

Registration Number: NCT05842681

Locations: 🇪🇬
Assiut university-Faculty of Medicine, Assiut, Egypt
🇪🇬
Faculty of Medicine Assuit University, Assiut, Egypt

Safety and Clinical Activity of Itolizumab in aGVHD

Phase 1

Recruiting

Conditions: Acute Graft Versus Host Disease

Interventions: Drug: Itolizumab
Drug: Methylprednisolone

First Posted Date: 2023-04-21

Last Posted Date: 2023-05-25

Lead Sponsor: Biotech Pharmaceutical Co., Ltd.

Target Recruit Count: 44

Registration Number: NCT05823675

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China